Safety concerns in animal tests led Arrowhead Pharmaceuticals to suspend testing of a closely watched drug for cystic fibrosis, the latest setback for an RNA-based medicine against the genetic lung disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,